Bioscience firm applies AI and data science to identify existing drugs Atozet and Cablivi as potentially effective therapies for blood clots and inflammation caused by COVID-19 CHARLOTTESVILLE, Va., Aug. 25, 2020 /PRNewswire/ — Two newly repositioned drugs with the potential to combat key symptoms of COVID-19 were announced today by Biovista, an AI-driven bioscience firm that … Read More
Year: 2020
Mechanistic analysis of Atorvastatin
Repositioning of Atorvastatin for the treatment of COVID-19. Statins such as Atorvastatin are potent cholesterol-lowering drugs that are tested against COVID-19. Statins could be proven beneficial particularly against SARS-CoV-2-induced cardiovascular manifestations. Explore the live graph.
Pathways and cell types related to Amantadine’s MoA in COVID-19
Amantadine is an anti-viral drug which is also used in Parkinson’s disease. The drug has been shown to reduce viral load in the context of the influenza virus, and in the COVID-19 setting, it may be able to decrease the viral load in SARS-CoV-2 positive patients. Explore the live graph.
Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome
Eculizumab is a biologic therapy, a complement C5 inhibitor, and has recently shown promise in COVID-19. The graph provides an important step towards elucidating the MoA of this drug in COVID-19. Explore the live graph.
Mechanistic analysis of combination IFB-a2b chlorpheniramine, ibuprofen
Chlorphenamine is a known antihistamine used to treat the symptoms of allergic conditions such as allergic rhinitis, whereas Ibuprofen is a potent nonsteroidal anti-inflammatory drug (NSAID). Combination of Chlorpheniramine and ibuprofen combination have long been postulated to treat common cold and its symptoms. Role and efficacy in the COVID-19 remains to be elucidated. Explore the … Read More